drugset / Trial / NCT03015948
A Single Dose Study of SHR4640 in Healthy Male Volunteers
RandomizedParallel-groupTriple-blindOther
Summary
This is a single-center, randomized, double-blind, placebo-controlled, single ascending-dose Phase I trial.
Timeline
- Start
- 2016-09-22
- Primary completion
- 2016-11-23
- Completion
- 2016-11-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SHR4640 | Small molecule | 2.5 mg | — |
| Subject | SHR4640 | Small molecule | 5 mg | — |
| Subject | SHR4640 | Small molecule | 10 mg | — |
| Subject | SHR4640 | Small molecule | 20 mg | — |